Should I buy or sell Enveric Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENVB shares. View ENVB analyst ratings or view top-rated stocks .

What is Enveric Biosciences' stock price target for 2024?

1 analysts have issued 1 year target prices for Enveric Biosciences' shares. Their ENVB share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,121.9% from the stock's current price. View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts .

How have ENVB shares performed in 2024?

Enveric Biosciences' stock was trading at $1.30 on January 1st, 2024. Since then, ENVB shares have decreased by 37.0% and is now trading at $0.8184. View the best growth stocks for 2024 here .

When is Enveric Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ENVB earnings forecast .

How were Enveric Biosciences' earnings last quarter?

Enveric Biosciences, Inc. (NASDAQ:ENVB) announced its quarterly earnings results on Monday, March, 25th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.55) by $0.09.

What ETF holds Enveric Biosciences' stock?

AdvisorShares Psychedelics ETF holds 278,833 shares of ENVB stock, representing 3.47% of its portfolio.

When did Enveric Biosciences' stock split?

Enveric Biosciences shares reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Enveric Biosciences?

Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENVB

Enveric Biosciences (ENVB) Stock Price, News & Analysis

→ Boost your retirement with these AI payouts (From InvestorPlace) (Ad)

Free ENVB Stock Alerts

$0.82

-0.02 (-2.21%)

(As of 05:49 PM ET)

Compare

Today's Range: $0.81
▼
$0.86
50-Day Range: $0.79
▼
$1.32
52-Week Range: $0.65
▼
$6.98

Volume: 112,076 shs
Average Volume: 3.11 million shs
Market Capitalization: $6.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Enveric Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,121.9% Upside
$10.00 Price Target
Short Interest: Healthy
1.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.17
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.98) to ($1.02) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Enveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Enveric Biosciences has received no research coverage in the past 90 days.
Read more about Enveric Biosciences' stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
1.07% of the float of Enveric Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Enveric Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Enveric Biosciences has recently decreased by 15.06%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Enveric Biosciences does not currently pay a dividend.
Dividend Growth
Enveric Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENVB.

1.0

News and Social Media Coverage

News Sentiment
Enveric Biosciences has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Enveric Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for ENVB on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.20% of the stock of Enveric Biosciences is held by insiders.
Percentage Held by Institutions
Only 13.82% of the stock of Enveric Biosciences is held by institutions.
Read more about Enveric Biosciences' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Enveric Biosciences are expected to grow in the coming year, from ($1.98) to ($1.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enveric Biosciences is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enveric Biosciences is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enveric Biosciences has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Read more about Enveric Biosciences' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Resource Stock Digest

Digitizing the $11T commodities sector with one tiny stock

One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector.

It’s an opportunity that likely won’t stay at these levels for long

About Enveric Biosciences Stock (NASDAQ:ENVB)

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

ENVB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENVB Stock News Headlines

May 16, 2024 | benzinga.com

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

May 15, 2024 | msn.com

Enveric Biosciences GAAP EPS of -$0.61

May 15, 2024 | businesswire.com

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 14, 2024 | msn.com

Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate

May 14, 2024 | businesswire.com

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 8, 2024 | msn.com

Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods

May 8, 2024 | businesswire.com

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

March 27, 2024 | benzinga.com

Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth

March 21, 2024 | uk.investing.com

Enveric Biosciences Inc (ENVB)

March 19, 2024 | msn.com

Why Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday?

March 19, 2024 | msn.com

Enveric gains on out-licensing deal of new chemical entities for joint disease treatments

March 19, 2024 | finance.yahoo.com

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

March 12, 2024 | finance.yahoo.com

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

March 4, 2024 | msn.com

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More

February 29, 2024 | investorplace.com

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

February 29, 2024 | markets.businessinsider.com

Enveric Signs Term Sheets To Pursue Out-licensing Of Three Classes Of Compounds

February 29, 2024 | businesswire.com

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

February 26, 2024 | finance.yahoo.com

CORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

February 23, 2024 | markets.businessinsider.com

Enveric Biosciences To Sell Cannabinoid-Related Cancer Intellectual Property; Stock Up In Pre-Market

February 23, 2024 | businesswire.com

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

February 21, 2024 | msn.com

Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds

February 21, 2024 | finance.yahoo.com

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 21, 2024 | businesswire.com

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 12, 2024 | msn.com

Psychedelic stocks gain after FDA priority review for MDMA therapy

February 10, 2024 | msn.com

Enveric Biosciences Granted Extension to Avoid Nasdaq Delisting

See More Headlines

Company Calendar

Last Earnings: 3/25/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ENVB
CUSIP: N/A
CIK: 890821
Web: jaypharma.co
Phone: (239) 302-1707
Fax: 732-243-9254
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +1,090.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -383.90%
Return on Assets: -204.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.48
Quick Ratio: 3.48

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 1.18

Miscellaneous

Outstanding Shares: 7,750,000
Free Float: 7,659,000
Market Cap: $6.51 million
Optionable: Not Optionable
Beta: 0.82

Key Executives

Dr. Joseph Edward Tucker Ph.D. (Age 55)
CEO & Director
Comp: $450.79k
Mr. Kevin M. Coveney CPA (Age 60)
Chief Financial Officer
Comp: $385.62k
Dr. Peter J. Facchini Ph.D. (Age 60)
Chief Innovation Officer
Comp: $233.27k

Key Competitors

View All Competitors

Insiders

Frank Pasqualone
Bought 1,000 shares on 9/15/2023
Total: $2,140.00 ($2.14/share)

View All Insider Transactions

ENVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Enveric Biosciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENVB shares.
View ENVB analyst ratings or view top-rated stocks.
What is Enveric Biosciences' stock price target for 2024?: 1 analysts have issued 1 year target prices for Enveric Biosciences' shares. Their ENVB share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,121.9% from the stock's current price.
View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts.
How have ENVB shares performed in 2024?: Enveric Biosciences' stock was trading at $1.30 on January 1st, 2024. Since then, ENVB shares have decreased by 37.0% and is now trading at $0.8184.
View the best growth stocks for 2024 here.
When is Enveric Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ENVB earnings forecast.

How were Enveric Biosciences' earnings last quarter?: Enveric Biosciences, Inc. (NASDAQ:ENVB) announced its quarterly earnings results on Monday, March, 25th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.55) by $0.09.
What ETF holds Enveric Biosciences' stock?: AdvisorShares Psychedelics ETF holds 278,833 shares of ENVB stock, representing 3.47% of its portfolio.
When did Enveric Biosciences' stock split?: Enveric Biosciences shares reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of Enveric Biosciences?: Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENVB) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Enveric Biosciences (ENVB) Stock Price, News & Analysis

Enveric Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest